Resources

In a landscape where efficiency, scalability, and quality are critical, automation is no longer just about doing more; it’s about understanding more. Olivia Dell-Price, Pharmaceutical Automation Specialist at Labman, explores how the future of biomanufacturing is becoming intelligent, connected and data-driven.

AI-powered protein engineering promises speed, precision and scalability - but only if you have the right data. For most teams, that’s the biggest barrier. For ACROBiosystems, it’s a decade-long advantage. Read this blog by Ruiyuan Zheng, Marketing Product Manager, ACROBiosystems, to learn more about how they solved it. 

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Slingshot Therapeutics Limited and is pleased to announce the placement of Dr John Isaac as Chief Scientific Officer.

Constructive Bio and RxCelerate have formed a strategic partnership to develop novel biologic therapeutic candidates targeting multiple disease indications, including liver fibrosis and other cardiometabolic diseases. Combining Constructive Bio’s pioneering programmable biology platform with RxCelerate’s expert drug design and development capabilities to drive innovation in engineered biologics for challenging diseases.

T-Therapeutics, a biotechnology company developing next-generation T cell receptor (TCR) therapeutics for cancer and autoimmune disease, today announces the successful expansion of its Series A financing, raising afurther $32 million. Following the initial $59 million raised, this brings the Series A total to date to $91 million.

The British Business Bank has announced a €30 million commitment to Sofinnova Partners (Sofinnova) new €650 million ($750 million) fund, Sofinnova Capital XI. 

The UK’s used nuclear materials will be recycled to create an evergreen supply of new precision cancer medicines, offering hope for patients with previously untreatable cancers.

London Life Sciences Week kicked off last night with a buzzing reception at Somerset House and we’re looking forward to a jam-packed week of networking and events. Great to see the incredible hard work from the BIA and L&P teams come to life – shining a global light on the incredible UK ecosystem. At the same time, we’re seeing the UK take a leading role in pro-innovation regulation, from last week’s enactment of the Precision Breeding Act to Lawrence Tallon’s insights on the MHRA’s proportionate, strategic future approach, and now need the government to invest in the sector and ensure the commercial environment enables the UK to build on this world-beating foundation.

Prokarium appoints Ibs Mahmood as Chief Executive Officer

Oxford-based techbio startup Scripta Therapeutics emerges from stealth by announcing a $12 million seed round to upend conventional approaches to drug discovery. Scripta combines AI, imaging, and patient-derived models to create and modulate disease maps based on transcriptional networks, building a new biology-first paradigm to decode and undo the programs that drive disease. The round is led jointly by Oxford Science Enterprises (OSE) and Apollo Health Ventures, with further investment from AlbionVC, YZR Capital, and Parkwalk Advisors, and support from Oxford University Innovation.

PIR International recently partnered with a PE-backed pharmaceutical services company in appointing a Chief Growth Officer.

LinkGevity's first-in-class Anti-Necrotic drug was featured in the Sunday Express this week. The article highlights the transformative potential of targeting necrosis- a long-overlooked driver of age-related degeneration.

The novel assay, developed with GenScript’s THE™ His Tag Monoclonal Antibodies, provides researchers with a ready-to-use solution for rapid, reliable measurement of His-tagged proteins.

The Medical Research Council, Wellcome Trust, and Innovate UK have today announced a major new £15.9 million initiative to enable the development of advanced, specific and highly reproducible human-based in vitro models of disease, to make them widely available to researchers in academia and industry.

MyAmici, a leading provider of LabOps solutions for biotech and life science organisations, is pleased to announce its strategic entry into the Swiss market through a partnership with Kisco Pharma Outsourcing Solutions. This collaboration marks a significant milestone in MyAmici’s European expansion and brings together two complementary organisations committed to empowering scientific innovation.

BIA’s influence and connect were out in force last week – grasping a timely opportunity to get our key Autumn Budget asks across impactfully to the Chancellor with the clear backing of over 200 member CEOs, and putting on a dynamic, pro-innovation Future of UK Regulation conference, featuring MHRA and NICE CEOs amongst other key stakeholders.

Brainomix earned top recognition in the Science category for its innovative approach to improving outcomes for patients affected by cardiovascular disease and stroke.

In this blog, Chris Sadler, Development Lead at Astrea Bioseparations Ltd, explores how combining multiple interaction mechanisms in chromatography can unlock new, cost-effective solutions for complex downstream challenges.

Worthwhile investments can be hard to recognise when discussing sustainability initiatives. Let's take a look at five with short payback periods.

​​​​​​​LinkGevity and Delta Biosciences, UAB, a Lithuanian pharmaceutical stability specialist, have been awarded funding from the UK Space Agency to prepare LinkGevity’s pioneering Anti-Necrotic therapeutic for deployment in space.